Inari Medical

36 articles with Inari Medical

• Inari Medical Announces Global Partnership with Aidoc to Advance the Timely Detection and Treatment of Pulmonary Embolism

  4/14/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced a new global partnership with Aidoc, the leading provider of enterprise artificial intelligence (“AI”) solutions, to accelerate the adoption and the clinical impact of AI to advance the timely detection and treatment of pulmonary embolism (“PE”).

• Inari Medical Announces First Patient Enrolled in FLAME Study

  4/5/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the enrollment of the first high-risk pulmonary embolism (“PE”) patient in the FlowTriever for Acute Massive Pulmonary Embolism study (“FLAME”).

• Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results

  3/9/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its fourth quarter and full year ended December 31, 2020.

• Inari Medical to Announce Fourth Quarter and Full Year 2020 Financial Results

  2/23/2021

  Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced it will release financial results for the fourth quarter and full year 2020 after market close on Tuesday, March 9, 2021.

• Inari Medical to Present in Upcoming Investor Conferences

  2/3/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the following upcoming investor conferences

• Inari Medical Announces Presentation of Positive Chronic Clot Subanalysis Results from Real World CLOUT Registry at LINC 2021

  1/25/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced strongly positive interim results of the first 64 chronic deep vein thrombosis (“DVT”) patients enrolled in the ClotTriever Outcomes Registry (“CLOUT”).

• Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue

  1/13/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue.

• Inari Medical’s FlowTriever System Receives FDA 510(k) Clearance for Treatment of Right Atrial Clot in Transit

  1/8/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced U.S. Food and Drug Administration (“FDA”) 510(k) clearance of the FlowTriever system for the treatment of clot in transit (“CIT”) in the right atrium.

• Inari Medical Appoints Venkat Tummala as VP of Medical Affairs and Justin Crockett as VP of Inari Solutions Group

  1/5/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointments of Venkat Tummala, MD to VP, Medical Affairs, and Justin Crockett to VP, Inari Solutions Group

• Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry

  11/13/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study.  FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (“PE”) patients.  The results were strongly posit

• Inari Medical Reports Third Quarter 2020 Financial Results

  11/12/2020

  Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its third quarter ended September 30, 2020.

• Inari Medical Appoints Kevin Strange as VP of Strategy and Business Development and Angela Ahmad as General Counsel

  11/12/2020

  Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel.

• Inari Medical to Participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

  11/6/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today that its management team will participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. About Inari Medical, Inc. Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, n

• Inari Medical to Announce Third Quarter 2020 Financial Results

  10/29/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020.

• Inari Medical Announces Presentation of Positive Results from First Patients in Real World FLASH Registry

  10/19/2020

  - Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive results of the first 230 patients enrolled in its FLASH study. Interim data of this real world pulmonary embolism (“PE”) population, including high- and intermediate-risk patients, was obtained across 19 US sites. Results were

• Inari Medical Prospective Clinical Data on the FlowTriever System to be Presented in Late-Breaking Session at TCT Connect

  9/21/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever

• Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer

  9/17/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020

• Inari Medical to Participate in Upcoming Investor Conferences

  8/27/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.

• Inari Medical Reports Second Quarter 2020 Financial Results

  8/11/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.

• Inari Medical to Present at the Canaccord Genuity 40th Annual Growth Conference

  7/29/2020

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference.